Biopharmaceutical company BOOST Pharma has appointed Hans Schambye as Chief Executive Officer.  

BOOST, a company developing novel, first–in–class off-the-shelf cell therapies for rare, debilitating paediatric skeletal diseases, announced Schambye has transitioned from his role on the Board of Directors with immediate effect into his new role as Chief Executive Officer on a full-time basis. 

Schambye is a biotech entrepreneur and operator with a proven record in building and leading companies from drug discovery to late-stage clinical development and pivotal value-creating milestones. He has expertise in operational leadership, clinical programme management, company growth, and financing and investor strategy.   

Schambye joins BOOST Pharma from Galecto Inc, where he served as President and CEO, leading the company through significant scientific, clinical, and financial milestones, and raising more than $500 million.  

The appointment comes as BOOST advances BT101, its lead cell therapy candidate for osteogenesis imperfecta (OI), a rare genetic disorder also known as brittle bone disease.  BT101 targets the root causes of OI and has shown promising clinical data in a Phase I/II trial, including more than 70% reduction in fractures in year one and approximately 78% reduction by year two, with the majority of patients experiencing no fractures at all in year two.   

“BOOST Pharma brings together world class science, a truly exceptional team, and a late–stage candidate with the potential to transform the lives of children with osteogenesis imperfecta,” Schambye said.  

 “The strength of the BT101 data to date, combined with its path toward Phase III, is incredibly compelling. I am deeply motivated by what this company has already achieved and excited to help accelerate clinical development to address a clear unmet need.”